Список литературы.

Поставить закладку

Yao, J-C. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States./ J-C. Yao, M.Hassan, A.Phan. et al. // J Clin Oncol 2008.- 26. - 3063–3072.
Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci. 1994 Sep 15;733:464-70.
Eriksson B, Klöppel G, Krenning E Ahlman H, Plöckinger U, Wiedenmann B, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumors– welldifferentiated jejuna-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8–19.
Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80(4):244-51.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi:10.1200/JCO.2009.22.8510.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158
Martín-Richard M, Massutí B, Pineda E, Alonso V, Marmol M, Castellano D, Fonseca E, Galán A, Llanos M, Sala MA, Pericay C, Rivera F, Sastre J, Segura A, Quindós M, Maisonobe P; TTD (Tumores del Tracto Digestivo) Study Group. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013 Sep 20;13:427. doi: 10.1186/1471-2407-13-427.
Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B, Pavel M. Impact of octreotide long- acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2013;98(2):137-43. doi: 10.1159/000353785. Epub 2013 Aug 13.
Oberg K. Interferon-alpha versus somatostatin or the combination of both in gastroenteropancreatic tumours. Digestion. 1996;57 Suppl 1:81-3
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. RAD001 in Advanced neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037
Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Endocr Relat Cancer. 2013 Oct 14;20(6):825-31. doi: 10.1530/ERC- 13-0254.
Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015 Jun;22(3):289-98. doi: 10.1530/ERC- 15-0075. Epub 2015 Mar 13
Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.
Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991 Jul 15;68(2):227-32.
Bajetta, B. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. / Bajetta B, Rimassa L, Carnaghi C, et al. // Cancer. – 1998. – 83. – Р. 372-378
Ekeblad, S. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. / S. Ekeblad, A. Sundin, ET. Janson et al. // Clin. Cancer. Res. – 2007. – 13. – Р. 2986-2991.
Bajetta, E. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low- grade and high-grade neuroendocrine tumours? / Bajetta, E, Catena L, Procopio G, et al. // Cancer Chemother. Pharmacol. – 2007. – 59. Р. 637-642.
Cassier, PA. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well- differentiated neuroendocrine carcinomas: a single-center experience./ PA. Cassier, T. Walter, B. Eymard et al. // Cancer. –2009. – 115. – Р. 3392-3399.